Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
| Autor: | Leader R; Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.; Acute Internal Medicine, University Hospital Aintree, Liverpool, UK., Cowen J; Accident and Emergency Medicine, University Hospital Aintree, Liverpool, UK., Rajeev SP; Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.; Diabetes & Endocrinology, University Hospital Aintree, Liverpool, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMJ case reports [BMJ Case Rep] 2019 Sep 19; Vol. 12 (9). Date of Electronic Publication: 2019 Sep 19. |
| DOI: | 10.1136/bcr-2019-231104 |
| Abstrakt: | Sodium glucose co-transporter-2 inhibitors (SGLT2-i) have become a popular therapeutic strategy in the management of hyperglycaemia in type 2 diabetes mellitus. The primary site of action of SGLT2-i is at the proximal renal convoluted tubule. They work by blocking SGLT2 receptors, sodium-dependent glucose co-transport molecules, which in turn prevents glucose reabsorption, facilitating glucosuria, improving glycaemic control as well as a moderate degree of weight loss. We report the case of a 51-year-old woman admitted to the acute medical unit with abdominal pain and vomiting, who was diagnosed with euglycaemic diabetic ketoacidosis secondary to recent initiation of an SGLT2-i medication (dapagliflozin). Clinicians should be aware of this rare side effect of SGLT2-i, to circumvent delays in patient management. Competing Interests: Competing interests: None declared. (© BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|